Auteur/autrice : jberthold

BLENDS

by jbertholdin Biotech, Institutions, Service Providers & others, Medtech, Pharma

BLENDS

About the company

Founded in 2023, Blends provides research intelligence for biotech companies and labs.

They deliver state-of-the-art systematic reviews within 24 hours using advanced methodologies, ensuring comprehensive and timely analysis that supports faster and more informed decision-making in research and development projects.

Their cutting-edge monitoring tools enhance productivity and effectiveness by offering real-time updates, enriched data, and unique insights into scientific developments. This includes features like Live, Reports, Trends, and Context, which transform how biotech information is accessed, analyzed, and applied, driving innovation and efficiency in the industry.

About the solution


Their cutting-edge monitoring tool is designed to keep researchers and labs fully informed about relevant scientific developments. It stands out with four main features: Live, Reports, Trends, and Context, each offering unique insights. Their platform enriches public data, providing summaries, key conclusions, importance indicators, and more, making research more exploitable than ever. Unlike competitors, their Context feature uniquely identifies analogies in unrelated research, fostering interdisciplinary breakthroughs.

Website
Key information

– Therapeutic areas: All therapeutic areas

– Based in: Versailles (FRANCE)

– Employees: 11 – 50

– Created in: 2023

OKOMERA

by jbertholdin Biotech

OKOMERA

About the company

Okomera specializes in automated 3D organoid screening technology that accelerates access to improved, precision-based cancer therapies. Their goal is to advance personalized medicine by providing healthcare actors with powerful tools to analyze how tumors respond to various therapies. 

Okomera integrates standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity.

About the solution

They have developed a miniaturized 3D assay to help clinical decision. Using a biopsy of the tumor, Okomera’s cell culture technology includes: a fluidic machine, reagents, and a software analysis designed to estimate and identify the best drug treatment for each cancer patient.

Website
Key information

– Therapeutic areas: Oncology, Assays on chip, Drug discovery

– Based in: Paris (FRANCE)
Berkeley (US)

– Employees: 11 – 50

– Created in: 2020

INSTITUT PASTEUR

by jbertholdin Institutions, Service Providers & others

INSTITUT PASTEUR

About the company

The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology,

About the solution

The Institut Pasteur’s outstanding research is facilitated by the development of a technological environment of the highest standard, with core facilities for nanoimaging (cryo-electron microscopy, cryo-electron tomography, etc.), computational biology and artificial intelligence.

Website
Key information

– Therapeutic areas: Emerging infectious diseases (COVID-19, Ebola, Zika, etc.), Antimicrobial resistance, Certain cancers, Neurodegenerative diseases (Alzheimer’s and Parkinson’s disease, etc.), Brain connectivity disorders (autism, depression, etc.)

– Based in: Paris (FRANCE)

– Employees: 500+

– Created in: 1887

VOISIN CONSULTING

by jbertholdin Institutions, Service Providers & others

VOISIN CONSULTING

About the company

Voisin Consulting Life Sciences (VCLS) is a team of around 300 life sciences professionals, committed to delivering innovative therapies to patients. From discovery to patients, their team of HealthTech product specialists offers integrated solutions from development planning, manufacturing, quality and control, nonclinical and clinical testing, clinical trial operations, safety monitoring, registration and commercialization, post-launch.

About the solution

With a presence in North America, Europe and Southeast Asia, they design global strategies and adapt execution in each market – accounting for local medical practices, regulatory frameworks and reimbursement landscapes. They have been interacting for more than two decades with regulators, payers and key opinion leaders in these markets. The privileged relationships that they have developed facilitate formal and informal dialogue between the industry and health authorities.

Website
Key information

– Therapeutic areas: Consulting in Life Sciences

– Based in: Boulogne (FRANCE)

– Employees: 201-500

– Created in: 1997

BANOOK GROUP

by jbertholdin Institutions, Service Providers & others

BANOOK GROUP

About the company

Banook Group is one of the few international providers able to offer services combining cardiac safety, centralized medical image reading and critical event adjudication on behalf of pharmaceutical groups, biotech companies, medical device manufacturers, CROs and non-profit organizations.
Its mission is to help its customers invent tomorrow’s healthcare, using innovative, high-quality and reliable solutions for all phases of development or marketing of new drug treatments.

Its medical and regulatory expertise, as well as its approach to quality and the availability of its team, make Banook a key player in the market for clinical trial services and medical tele-expertise.

Created in 1999, the Banook Group operates internationally from Nancy (head office), Munich (Germany), Montreal (Canada) and Boston (USA).

About the solution

Customer & science oriented, you will benefit from 25 years of expertise with its human-sized team.

Website
Key information

– Therapeutic areas: All therapeutic areas, Clinical Development

– Based in: Headquarter : Nancy (FRANCE)
Office: Boston (US)

– Employees: 51 – 200

– Created in: 1999

OXFORD BIOMEDICA

by jbertholdin Institutions, Service Providers & others

OXFORD BIOMEDICA

About the company

Oxford Biomedica (also known as OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors and other viral vector types. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB is headquartered in Oxford, UK. It has 14 GMP production suites with bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, US. OXB offers

About the solution

OXB has unique experience in developing and manufacturing lentiviral vector, AAV and adenoviral vector with expert capabilities from plasmid design to commercial GMP manufacturing and fill finish. OXB was the first commercial supplier of LV for a CAR-T product in the world. OXB has taken more than 30 customers’ projects to IND.

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB also offers adenovirus and MVA vaccine production services and has process development capabilities and analytical methods accepted by regulatory authorities enabling the delivery of projects from pre clinical to commercial stages.

OXB has unique in-house analytical development capabilities to characterise vector and achieve rapid batch release, included automated assays and advanced mass spectroscopy.

Additionally, OXB offers regulatory authoring and reviewing support for IND/IPMD, BLA/MAA submissions.

Website
Key information

– Therapeutic areas: Cell and gene therapy, Vaccines

– Based in: Strasbourg & Lyon (FRANCE), Massachussetts (US)

– Employees: 500+

– Created in: 1996

ESSONNE DEVELOPPEMENT

by jbertholdin Institutions, Service Providers & others

ESSONNE DEVELOPPEMENT

About the company

Essonne Développement is the territorial development agency of Essonne County. The agency supports the development and attractiveness of the territory and helps companies grow from local resources.

About the solution

The county has a competitive advantage in six industrial fields: biotechnology, optic-photonic, quantum, artificial intelligence, agricultural and food technology. Essonne is a prime location for international biotechnology companies regarding the development of the first french biocluster Genopole and the high concentration of R&D activity in Paris-Saclay area.

Website
Key information

– Therapeutic areas: Territorial Development Agency

– Based in: Evry-Courcouronnes (FRANCE)

– Employees: 11-50

– Created in: 1989

DEV’UP

by jbertholdin Institutions, Service Providers & others

DEV’UP Centre
Val de Loire

About the company

DEV’UP Centre-Val de Loire is an economic development agency located north of Paris. It is France’s 1st region in terms of specialization and attractiveness in the healthcare sector. They coordinate investment projects and partnerships (companies, laboratories, technical centers, etc.) in the healthcare sector. They recently welcomed the largest French industrial investment in the sector (2.1 billion) with Novo Nordisk. They work in coordination with Business France offices to support investment projects in the region.

About the solution

DEV’UP provides tailor-made support for foreign investment in their region:
– identifying technological partners
– hosting solutions in specialized incubators, industrial site solutions
– recruitment and training
– access to financial aid (including the France 2030 program) and investment funds.

Website
Key information

– Therapeutic areas: All therapeutics area, Regional Development Agency

– Based in: Centre Val de Loire (FRANCE)

– Employees: 11-50

– Created in: 2011

SURGIMAB

by jbertholdin Biotech, Pharma

SURGIMAB

About the company

SurgiMab’s tumor-targeting fluorescent molecules enable real time visualization of tumor margins and micro-tumors which are invisible to the naked eye.

After injection to the patient, SurgiMab’s lead molecule SGM-101 specifically targets various lesions such as colorectal, pancreas or lung tumors. Surgical navigation then allows tumors to be displayed intra-operatively, allowing complete resection. In case of recurrent cancer, when fibrotic tissue sometimes impairs the surgeon’s vision, it can also help the surgeon preserve important structures.
Intraoperative tumor imaging with SurgiMab’s targeted molecules represents a real-time improvement in the intraoperative differentiation between normal and cancer tissue. It will participate in the new paradigm-shift in cancer surgery: surgeons will improve patient outcome while lowering health-care costs.

SurgiMAb was created in 2011. SGM-101 is currently tested in the clinic in the USA and Europe, including two Phase 3 studies.
SurgiMab is seeking additional financing and/or parners to get to the market.

About the solution

As opposed to an indiscriminate contrast agent, this ability to specifically highlight malignant tissue during a procedure opens up a broad market in both Fluorescence Guided Surgery and potentially also in cancer screening.

SurgiMab’s technique of intraoperative detection of tumors combines the specificity of monoclonal antibodies and the sensitivity of fluorescent detection. To date SGM-101 is the only cancer-targeting fluorescent molecule with efficacy demonstrated in the clinic for several digestive tumors. Surgeons can rely on fluorescence imaging to assess surgical margins, accurately stage cancer and detect small invisible metastases or to spare normal tissue.

Website
Key information

– Therapeutic areas: Oncology, Surgery, Molecular Imaging

– Based in: Montpellier (FRANCE)

– Employees: 1-10

– Created in: 2011

ROOWIN SA

by jbertholdin Biotech, Institutions, Service Providers & others, Pharma

ROOWIN SA

About the company

Roowin is a privately owned Contract Research Organisation (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value added fine chemistry, Roowin offers a large range of chemical services.

They support their customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches (about 20 kg).

About the solution

They are a french company specializing in high-value fine chemistry, is well-equipped to support biotech companies in need of GLP and GMP lots for toxicology studies and IND applications. With expertise in GMP synthesis and a focus on assisting customers from early research to later stages, Roowin is a potential partner for biotechs developing new clinical candidates.

Website
Key information

– Therapeutic areas: All therapeutic area

– Based in: La Varenne (FRANCE), Offices in San Diego (US)

– Employees: 11-50

– Created in: 1998